Navigation Links
Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets
Date:2/24/2009

LONDON, February 24 /PRNewswire/ --

- Syndicate Comprises Leading Sector Investors Clarus Ventures, MVM Life Science Partners and Novartis Option Fund

Heptares Therapeutics Ltd, the drug discovery company focused on drugs targeting G-protein-coupled receptors (GPCRs), announces today it has raised GBP21 million (US$30 million) of equity finance in a successful Series A private round from three blue-chip international venture capital firms. Clarus Ventures led the syndicate, which includes the founding investor, MVM Life Science Partners, and the Novartis Option Fund. All three investors contributed equally.

Michael Steinmetz for Clarus Ventures and Anja Koenig for the Novartis Option Fund have joined the Heptares Board of Directors as non-executive directors.

Over the next three years, Heptares intends to use the new funds to develop its own pipeline of small-molecule drug candidates using its proprietary StaR(TM) technology platform. These novel drug candidates will be developed against currently intractable GPCRs that are highly validated targets for the treatment of disease. Further progress in the application of StaR technology over this period is also expected to yield commercial partnering opportunities outside Heptares' core focus, for example, improved therapeutic antibodies against GPCRs.

GPCRs play a crucial role in many diseases and are the site of action of 25-30% of current drugs; as such they represent a major area of interest for pharmaceutical companies. However, these membrane proteins are notoriously difficult to isolate from cells in an intact and active form and this has severely restricted efforts to study GPCRs using modern drug discovery techniques.

Heptares' StaR (Stabilised Receptor) technology platform enables the Company to overcome this technology hurdle by engineering and purifying GPCRs in stable and functional conformat
'/>"/>

SOURCE Heptares Therapeutics Ltd
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Sopherion Therapeutics Secures $55 Million in Series C Funding
2. Northwest Biotherapeutics Secures $700,000 Equity Financing
3. Intelligroup Secures Multi-Million Dollar COSMOS Implementation with Almac Clinical Services
4. TaiGen Biotechnology Secures 37 Million USD in Series C Round Financing
5. Pharmacyclics Secures $5.0 Million in Debt Financing
6. EcoSphere(R) Biolatex(TM) Secures Funding from Granholm and Invest Michigan!
7. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
8. Queens secures £25M for UKs cyber safety
9. Queens secures £25m for UKs cyber-safety
10. Northwest Secures US$1.65 Million Debt Financing
11. NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013 The New Jersey chapter of ... Data Processing Associates (BDPA), is hosting its 10th annual ... This all-day event will encourage students and their parents ... and outs from many of the industries’ finest teachers. ... New Jersey Institute of Technology, the event will include ...
(Date:5/23/2013)... Korea , May 23, 2013 ... SillaJen, Inc., a private biotherapeutics and contract research ... biological products for cancer, announced today a publication ... patients treated with the oncolytic and immunotherapeutic vaccinia ... This research was published in the May 15 ...
(Date:5/23/2013)... Bed bugs compromised Penn State. ... confirmed it. Meanwhile, My Cleaning Products offered complimentary samples of ... the pests without using harmful chemical elements. , Based ... the affected building was actually a dormitory , My ... made on May 13 and bed bug presence was confirmed ...
(Date:5/22/2013)... 22, 2013 Oven Industries announces the ... integrated potentiometers or via a PC through the TTL ... and one half inches square can deliver up to ... switched, low noise solid state relay. Operator safety is ... the communication port and sensor input. Specifications: Input ...
Breaking Biology Technology:Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3Penn State Dorm Infested with Bed Bugs, My Cleaning Products Offers Complimentary Sample of Bed Bug Spray to Help Bed Bug Victims 2New AC Temperature Controller Announced by Oven Industries 2
... DX Frequently Changes Treatment ... Recommendations in Clinical Practice -, REDWOOD CITY, Calif., Nov. ... the publication of results from a study,indicating that Oncotype DX(R) ... The study, published in the,October issue of the American Journal ...
... China, Nov. 10 /Xinhua-PRNewswire/ -- 3SBio Inc. (Nasdaq:,SSRX), ... and marketing biopharmaceutical products primarily in China,today announced ... Food and Drug,Administration (SFDA) for approval of NuLeusin ... carcinoma. If approved, NuLeusin is expected to,be the ...
... New Data Presented at the Meeting Report the ... Benefit From Tight Glycemic Control in,Diabetics, MONTVALE, ... SYI ) today announced at the Annual Scientific,Sessions ... Orleans, that a,new clinical test to determine haptoglobin ...
Cached Biology Technology:Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated 2Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated 3Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated 43SBio Inc. Files for SFDA Approval of NuLeusin 23SBio Inc. Files for SFDA Approval of NuLeusin 33SBio Inc. Files for SFDA Approval of NuLeusin 4Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association 2Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association 3Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association 4Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association 5
(Date:5/21/2013)... COLUMBIA, Mo. Cancers of all types become most ... body. Once cancer has reached this stage, it becomes ... numerous tumors that can develop. Now, researchers at the ... radioactive nanoparticles that target lymphoma tumor cells wherever they ... professor of oncology in the MU College of Veterinary ...
(Date:5/21/2013)... and health stores, phosphatidylserine is a natural food ... to improve cognition and slow memory loss, it,s ... impairment. Now a team headed by Prof. Gil ... University,s Department of Human Molecular Genetics ... functioning of genes involved in degenerative brain disorders, ...
(Date:5/21/2013)... in shape is an uphill battle? Try staying fit ... weightlessness withers muscle and bone. , That,s the challenge ... with a new three-year, $1.2 million grant from NASA. ... during multiyear exploratory missions. , "You could give astronauts ... can,t get them to stick to it, it isn,t ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2Common food supplement fights degenerative brain disorders 2Fueling fitness on the final frontier 2
... N.Y. A cell,s genome maintains its integrity by ... of DNA called heterochromatin. In the comparatively simple organism ... (RNAi) plays an essential role in assembling heterochromatin, which ... state. Central to this process is a large protein ...
... Researchers at Harvard Medical School and Children,s Hospital ... infection as it spread among cystic fibrosis patients by ... contained. A significant achievement in genetic pathology, the work ... see evolution as it happensand sheds new light on ...
... higher levels of high sensitivity C-Reactive protein (hsCRP) and shorter ... patients, in research presented at the American Heart Association,s Scientific ... intake from food, heart failure patients in the study who ... to have higher levels of hsCRP, a marker for inflammation ...
Cached Biology News:CSHL team solves a protein complex's molecular structure to explain its role in gene silencing 2Bacterial genes tell the tale of an outbreak's evolution 2Bacterial genes tell the tale of an outbreak's evolution 3Bacterial genes tell the tale of an outbreak's evolution 4Low vitamin C levels may raise heart failure patients' risk 2
... allows detection of SYBR Green I or ... range of fluorophores in the second channel ... for a multitude of applications such ... thermal cycler offers precision thermal control and ...
Fingerprinting II database sharing tools is an optional module for the Fingerprinting II Basic software package that enables peer-to-peer data exchange over the internet and provides external databas...
Fingerprinting II dimensioning techniques is an optional module that adds principal component analysis, multidimensional scaling, discriminant analysis and MANOVA, and self-organizing maps to the Fin...
... II Informatix dimensioning ... optional module that ... analysis, multidimensional scaling, ... MANOVA, and self-organizing ...
Biology Products: